Detalles de la búsqueda
1.
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
N Engl J Med;
386(6): 509-520, 2022 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34914868
2.
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.
Clin Infect Dis;
77(11): 1521-1530, 2023 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37466374
3.
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.
Infection;
51(5): 1273-1284, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36648627
4.
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial.
Ann Intern Med;
175(8): 1126-1134, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35667065
5.
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Clin Infect Dis;
73(11): e4539-e4548, 2021 12 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32785589
6.
The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.
J Infect Chemother;
27(2): 262-270, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33191112
7.
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
Clin Infect Dis;
70(9): 1799-1808, 2020 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31400759
8.
Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.
Antimicrob Agents Chemother;
64(5)2020 04 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32094127
9.
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
J Antimicrob Chemother;
72(9): 2616-2626, 2017 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28575389
10.
Reply to Sfeir.
Clin Infect Dis;
72(8): 1485-1486, 2021 04 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32634242
11.
Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
Antimicrob Agents Chemother;
60(10): 6234-43, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27503659
12.
Ertapenem prophylaxis of surgical site infections in elective colorectal surgery in China: a multicentre, randomized, double-blind, active-controlled study.
J Antimicrob Chemother;
69(12): 3379-86, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25151205
13.
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).
Microbiol Spectr;
12(3): e0356323, 2024 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38299867
14.
Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes.
Clin Pharmacol Ther;
113(6): 1337-1345, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37017631
15.
Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.
JAC Antimicrob Resist;
5(2): dlad011, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36880088
16.
Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis.
Open Forum Infect Dis;
10(6): ofad225, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37383243
17.
Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial.
J Clin Pharmacol;
63(12): 1387-1397, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37562063
18.
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
Infect Dis Ther;
12(12): 2725-2743, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37995070
19.
Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial.
J Infect;
87(5): 392-402, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37690669
20.
Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
CPT Pharmacometrics Syst Pharmacol;
12(12): 1859-1871, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37798914